我院万古霉素和利奈唑胺临床应用分析  

Clinical Application of Vancomycin and Linezolid in Our Hospital

作　　者：蔡芸[1] 陈超[1] 郭代红[1] 白楠[1] 梁蓓蓓[1] 王睿[1] 

机构地区：[1]解放军总医院药品保障中心,北京100853

出　　处：《中国药师》2011年第9期1324-1326,共3页China Pharmacist

基　　金：国家自然基金青年科学基金项目(编号:81000755);2010年北京市科技新星项目(编号:2010B079);解放军总医院药品保障中心合理用药调研项目(编号:2010-Z25)

摘　　要：目的:评价抗耐甲氧西林金黄色葡萄球菌(MRSA)药物万古霉素和利奈唑胺在临床的应用情况。方法:对本院2008年1月～2010年9月万古霉素(含去甲万古霉素)和利奈唑胺的相关数据进行统计、分析。结果:万古霉素和利奈唑胺在本院有23个科室应用。骨科是抗MRSA药物用量最多的科室,其次为神经外科和呼吸科。2008～2010年万古霉素用量基本呈波动性增长;利奈唑胺片和注射剂均稳步增长;去甲万古霉素的用量变化不大。结论:本院万古霉素和利奈唑胺的应用基本合理,目前仍以万古霉素为主,可适当加强利奈唑胺的探索性临床研究,从而减轻万古霉素的用药压力。Objective： To evaluate the application status of vancomycin and linezolid in our hospital. Method： The data of the clinical application of vancomyein （including norvancomyein） and linezolid during January 2008 and September 2010 were analyzed statistically. Result： Vancomycin, norvancomycin and linezolid were used in 23 departments of our hospital. The amount of anti-MRSA antibiotics was the largest in orthopedics, followed by neurosurgery and respiratory department. During the year of 2008-2010 ,the application amount of vancomycin showed a fluctuant growth, linezolid showed a steady growth,while little change was found in the amount of norvancomycin. Conclusion： Application of vancomycin and linezolid is basically rational. Vaneomycin is the main choice of anti-MRSA. More exploratory clinical research on linezoild is needed to reduce the medication pressure of vancomycin.

关 键 词：耐甲氧西林金黄色葡萄球菌 万古霉素 去甲万古霉素 利奈唑胺 分析 

分 类 号：R978.19[医药卫生—药品]